Everything you care about in one place
Follow feeds: blogs, news, RSS and more. An effortless way to read and digest content of your choice.
Get Feederfeeder.co
AZ - Early R&D
Get the latest updates from AZ - Early R&D directly as they happen.
Follow now < 10 followers
Latest posts
Last updated about 6 hours ago
New PROTACs reported in Prelude Therapeutics patent | BioWorld
about 12 hours ago
... (VHL)-binding moiety coupled to a probable global transcription activator SNF2L2 (SMARCA2...
Phase 2 Trial of BMF-219 in Participants With Type 1 Diabetes Mellitus
6 days ago
Conditions: Type 1 Diabetes Mellitus Interventions: Drug: BMF-219 Sponsors: Biomea Fusion Inc...
SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
6 days ago
Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation; Acute Myeloid Leukemia With KMT2A...
One drug, two cleanup crews: A built-in backup for targeted protein degradation - MSN
6 days ago
... SMARCA2/4, the central ATPase subunits of the BAF chromatin remodeling complex...
Foghorn Therapeutics discloses new EP300 degradation inducers | BioWorld
6 days ago
Foghorn Therapeutics patents new CBP degradation inducers · Foghorn Therapeutics discovers new...
One drug, two cleanup crews: A built-in backup for targeted protein degradation - Phys.org
7 days ago
... SMARCA2 BD (green), glued by compound 1 (gray). Credit: Dmitri Segal...
Monovalent Degraders Enable Tunable SMARCA 2/4 Degradation - Bioengineer.org
7 days ago
... capable of recruiting two distinct E3 ubiquitin ligases simultaneously to orchestrate...
First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia
7 days ago
Conditions: Advanced Malignant Neoplasm; Acute Myeloid Leukemia; Mixed Lineage Leukemia; Mixed Lineage...
Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene
7 days ago
Conditions: Acute Myeloid Leukemia With KMT2A Rearrangement; Acute Myeloid Leukemia With NPM1...
Prelude Therapeutics Inc 1Q 2026: Revenue $4.58M, EPS $(0.13) — 10-Q Summary
8 days ago
... SMARCA2/4 payload programs have shown preclinical proof-of-concept. Portfolio focus: The company...
One drug, two cleanup crews: A built-in backup for targeted protein degradation | EurekAlert!
8 days ago
... SMARCA2 BD (green), glued by compound 1 (gray). © Dmitri Segal...
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
8 days ago
Conditions: Acute Myeloid Leukemia (AML) Interventions: Drug: Ziftomenib; Drug: Placebo; Drug: Venetoclax...